A review of the regulatory framework for personalized bacteriophages registration
Open Access
- 14 November 2020
- journal article
- review article
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 65 (5) , 259-266
Abstract
The increasing trend in antimicrobial resistance of pathogenic bacteria dictates the need for alternative solutions. Bacteriophages are bacterial viruses that kill their hosts during the lifecycle. The high specificity of phages makes the production of personalized cocktails the best option. Registration of drugs with variable composition lies beyond the current legal policies. In the present review, we studied the regulatory framework of the top 10 world economies from the point of personalized bacteriophages registration. We underlined procedures that countries can learn from each other.Keywords
This publication has 15 references indexed in Scilit:
- Decision analysis on entering the China pharmaceutical market: Perspectives from Taiwanese companiesComputers & Industrial Engineering, 2018
- Resistance Development to Bacteriophages Occurring during Bacteriophage TherapyViruses, 2018
- The Magistral PhageViruses, 2018
- Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of BacteriophagesCurrent Microbiology, 2016
- Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe ResolutionEuropean Journal of Hospital Pharmacy, 2016
- Mammalian Host-Versus-Phage immune response determines phage fate in vivoScientific Reports, 2015
- Paving a regulatory pathway for phage therapyEMBO Reports, 2013
- What are the limitations on the wider therapeutic use of phage?Bacteriophage, 2013
- The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extractsJournal of Allergy and Clinical Immunology, 2012
- The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?Pharmaceutical Research, 2010